Reyes Nicolás de Blas, Miriam Menacho Román, Ignacio Arribas Gómez, Paula Orejas Rodríguez-Marqués, Rubén Gómez Rioja
Introduction: To ensure adequate quality of clinical samples, laboratories must control samples' postanalytical preservation. We checked the stability limit of lactate dehydrogenase (LDH) and confirmed the 72-hour limit the manufacturer proposes, then evaluated sample stability under our working conditions using new recommendations for stability studies.
Methods: Leftover outpatient samples were randomly selected. Serum tubes with separator gel were used for primary sample collection. In a preliminary study of samples from 6 patients, we made determinations at baseline, 24, 48, and 72 hours for aliquots stored at room temperature and refrigerated. An extended study in refrigerated samples was performed on 10 samples of leftover serum at baseline and 12, 24, 36, 48, 60, and 72 hours.
Results: We found no substantial variation in samples at room temperature. In the extended study, an LDH decrease of 1.5% per day is expected up to 72 hours based on the formula PD% = 0.064 ×time [h].
Discussion: The available literature on stability studies is extensive and varies in terms of working methodology. Therefore, laboratories should follow recommendations from standardized and updated documents. We modified manufacturer stability recommendations by reducing the stability of refrigerated LDH samples in our laboratory automation system from 72 hours to 48 hours.
{"title":"Stability study of lactate dehydrogenase activity in serum samples at different temperatures and times according to Spanish Society of Laboratory Medicine recommendations.","authors":"Reyes Nicolás de Blas, Miriam Menacho Román, Ignacio Arribas Gómez, Paula Orejas Rodríguez-Marqués, Rubén Gómez Rioja","doi":"10.1093/labmed/lmaf062","DOIUrl":"10.1093/labmed/lmaf062","url":null,"abstract":"<p><strong>Introduction: </strong>To ensure adequate quality of clinical samples, laboratories must control samples' postanalytical preservation. We checked the stability limit of lactate dehydrogenase (LDH) and confirmed the 72-hour limit the manufacturer proposes, then evaluated sample stability under our working conditions using new recommendations for stability studies.</p><p><strong>Methods: </strong>Leftover outpatient samples were randomly selected. Serum tubes with separator gel were used for primary sample collection. In a preliminary study of samples from 6 patients, we made determinations at baseline, 24, 48, and 72 hours for aliquots stored at room temperature and refrigerated. An extended study in refrigerated samples was performed on 10 samples of leftover serum at baseline and 12, 24, 36, 48, 60, and 72 hours.</p><p><strong>Results: </strong>We found no substantial variation in samples at room temperature. In the extended study, an LDH decrease of 1.5% per day is expected up to 72 hours based on the formula PD% = 0.064 ×time [h].</p><p><strong>Discussion: </strong>The available literature on stability studies is extensive and varies in terms of working methodology. Therefore, laboratories should follow recommendations from standardized and updated documents. We modified manufacturer stability recommendations by reducing the stability of refrigerated LDH samples in our laboratory automation system from 72 hours to 48 hours.</p>","PeriodicalId":94124,"journal":{"name":"Laboratory medicine","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145305108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Darryl E Palmer-Toy, Rui Yan, Komal J Narwaney, Aida Legaspi, Michael Aragones, Jessica A Lam, John M Chang, Cecilia Portugal, Katia J Bruxvoort, Jason M Glanz, Ingrid A Binswanger
Introduction: This prospective study assessed relationships between COVID-19, humoral immunity, and common laboratory test results.
Methods: Blood and urine were collected from adults with clinical SARS-CoV-2 test results before August 2021: nucleic acid amplification (NAA) tests and antinucleocapsid protein (αN) serology. Measurements were made of αN and 13 laboratory tests, and results were compared across groups defined by NAA and αN status.
Results: Glycated hemoglobin (HbA1c) and platelet counts were clinically significantly higher among individuals who had COVID-19 than in individuals without evidence of COVID-19. Hemoglobin was more abnormal among patients without evidence of COVID-19. Glycated hemoglobin results were also much higher among patients with prior positive NAA and current or prior positive αN results than in individuals with negative αN results. No other statistically significant associations between NAA or αN and abnormal laboratory results were found.
Discussion: Elevated HbA1c results were associated with prior positive NAA findings combined with positive αN results but not with negative αN results. Further investigation into the association of dysregulated glycemic control with humoral immunity to natural infection is warranted, given the well-documented increase in incidence in type 1 and type 2 diabetes following COVID-19. Prior positive NAA results were also associated with a few nonspecific abnormalities of the complete blood cell count.
{"title":"SARS-CoV-2 humoral immunity is associated with elevated hemoglobin A1c.","authors":"Darryl E Palmer-Toy, Rui Yan, Komal J Narwaney, Aida Legaspi, Michael Aragones, Jessica A Lam, John M Chang, Cecilia Portugal, Katia J Bruxvoort, Jason M Glanz, Ingrid A Binswanger","doi":"10.1093/labmed/lmaf036","DOIUrl":"10.1093/labmed/lmaf036","url":null,"abstract":"<p><strong>Introduction: </strong>This prospective study assessed relationships between COVID-19, humoral immunity, and common laboratory test results.</p><p><strong>Methods: </strong>Blood and urine were collected from adults with clinical SARS-CoV-2 test results before August 2021: nucleic acid amplification (NAA) tests and antinucleocapsid protein (αN) serology. Measurements were made of αN and 13 laboratory tests, and results were compared across groups defined by NAA and αN status.</p><p><strong>Results: </strong>Glycated hemoglobin (HbA1c) and platelet counts were clinically significantly higher among individuals who had COVID-19 than in individuals without evidence of COVID-19. Hemoglobin was more abnormal among patients without evidence of COVID-19. Glycated hemoglobin results were also much higher among patients with prior positive NAA and current or prior positive αN results than in individuals with negative αN results. No other statistically significant associations between NAA or αN and abnormal laboratory results were found.</p><p><strong>Discussion: </strong>Elevated HbA1c results were associated with prior positive NAA findings combined with positive αN results but not with negative αN results. Further investigation into the association of dysregulated glycemic control with humoral immunity to natural infection is warranted, given the well-documented increase in incidence in type 1 and type 2 diabetes following COVID-19. Prior positive NAA results were also associated with a few nonspecific abnormalities of the complete blood cell count.</p>","PeriodicalId":94124,"journal":{"name":"Laboratory medicine","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12822492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145380266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Fen Wang, Lingbin Shu, Jinyi Liu, Jiacheng Lai, Xiaofeng Yang
Introduction: Early identification of whether bloodstream infections (BSIs) are caused by gram-negative or gram-positive bacteria is crucial for initiating timely and appropriate antibiotic treatment. This study aimed to investigate potential laboratory markers for predicting the type of bacterial infection in patients with suspected BSI.
Methods: Patients who presented at the emergency department with positive blood cultures were included in this study. Clinical and laboratory data collected within the first 24 hours of admission were analyzed.
Results: The study included 338 patients. Clinically significant differences in platelet count and procalcitonin (PCT) level were observed between patients with gram-positive and gram-negative infections. Platelet counts and PCT levels as predictors of infection were relatively ineffective, however, with receiver operating characteristic (ROC) area under the curve (AUC) values of 0.63 and 0.66, respectively. Subsequently, a specific cluster of patients characterized by normal to high platelet counts (170-318 ×109/L) and mildly elevated PCT levels (0-31.06 ng/mL) was identified using k means clustering. In this cluster, platelet counts of 284 ×109/L or higher combined with PCT levels of 2.73 ng/mL or less demonstrated a sensitivity of 70.3%, a specificity of 78.9%, and ROC AUC values of 0.82 for predicting gram-positive bacterial infections.
Discussion: The combined use of platelet count and PCT level could predict gram-positive bacterial infections in specific populations. This study may provide a practical strategy for the rapid identification of bacterial groups in patients with suspected BSI.
{"title":"Evaluation of platelet count and procalcitonin in differentiating gram-negative and gram-positive bacterial infection in emergency department patients: a retrospective cohort study.","authors":"Fen Wang, Lingbin Shu, Jinyi Liu, Jiacheng Lai, Xiaofeng Yang","doi":"10.1093/labmed/lmaf081","DOIUrl":"https://doi.org/10.1093/labmed/lmaf081","url":null,"abstract":"<p><strong>Introduction: </strong>Early identification of whether bloodstream infections (BSIs) are caused by gram-negative or gram-positive bacteria is crucial for initiating timely and appropriate antibiotic treatment. This study aimed to investigate potential laboratory markers for predicting the type of bacterial infection in patients with suspected BSI.</p><p><strong>Methods: </strong>Patients who presented at the emergency department with positive blood cultures were included in this study. Clinical and laboratory data collected within the first 24 hours of admission were analyzed.</p><p><strong>Results: </strong>The study included 338 patients. Clinically significant differences in platelet count and procalcitonin (PCT) level were observed between patients with gram-positive and gram-negative infections. Platelet counts and PCT levels as predictors of infection were relatively ineffective, however, with receiver operating characteristic (ROC) area under the curve (AUC) values of 0.63 and 0.66, respectively. Subsequently, a specific cluster of patients characterized by normal to high platelet counts (170-318 ×109/L) and mildly elevated PCT levels (0-31.06 ng/mL) was identified using k means clustering. In this cluster, platelet counts of 284 ×109/L or higher combined with PCT levels of 2.73 ng/mL or less demonstrated a sensitivity of 70.3%, a specificity of 78.9%, and ROC AUC values of 0.82 for predicting gram-positive bacterial infections.</p><p><strong>Discussion: </strong>The combined use of platelet count and PCT level could predict gram-positive bacterial infections in specific populations. This study may provide a practical strategy for the rapid identification of bacterial groups in patients with suspected BSI.</p>","PeriodicalId":94124,"journal":{"name":"Laboratory medicine","volume":"57 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146014018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Halimat Olaniyan, Jennifer Beckman, Elizabeth Crosby, David Shepherd, Rejwi A Dahal
Introduction: Fentanyl, a highly potent synthetic opioid, has contributed to a rapid rise in opioid-related overdoses and fatalities nationwide. Consequently, the need for accurate and timely testing for fentanyl has become critical. Immunoassay screens, reported as presumptive positive or negative, help address this need. We sought to compare the clinical performance of 2 US Food and Drug Administration (FDA)-approved fentanyl immunoassays-the Thermo Scientific DRI Fentanyl II Drugs of Abuse Assay and the Lin-Zhi International LZI Fentanyl (Q) Enzyme Immunoassay-for detection of fentanyl and its metabolites in urine, using liquid chromatography-tandem mass spectrometry (LC-MS/MS) as the reference method.
Methods: A total of 806 urine specimens were screened using 2 FDA-approved fentanyl immunoassays on Beckman Coulter DxC 700 AU Chemistry Analyzer. Of these specimens, 183 that were both positive and negative by immunoassay were further analyzed by LC-MS/MS for the presence or absence of fentanyl, norfentanyl, and 4-anilino-N-phenethylpiperidine (4-ANPP).
Results: Of the 806 specimens, 786 (98%) provided concordant results and 20 (2%) had discordant results between the 2 immunoassays. Concordance between immunoassays and LC-MS/MS was 97% for the LZI assay and 89% for the DRI assay. Among the 183 specimens tested, 4-ANPP was detected in 13 (7%).
Discussion: The 2 assays demonstrated comparable clinical utility for incorporation into a urine drug screen panel.
芬太尼是一种强效的合成阿片类药物,已导致全国阿片类药物过量和死亡人数迅速上升。因此,对芬太尼进行准确和及时的检测变得至关重要。报告推定阳性或阴性的免疫测定筛查有助于解决这一需求。我们采用液相色谱-串联质谱(LC-MS/MS)作为参比方法,比较美国食品和药物管理局(FDA)批准的两种芬太尼免疫测定法——Thermo Scientific DRI fentanyl II药物滥用测定法和Lin-Zhi International LZI fentanyl (Q)酶免疫测定法检测尿液中芬太尼及其代谢物的临床性能。方法:采用经fda批准的2种芬太尼免疫分析法,在Beckman Coulter DxC 700 AU化学分析仪上对806份尿液标本进行筛选。其中183例免疫测定阳性和阴性的标本,进一步采用LC-MS/MS分析芬太尼、去芬太尼和4-苯胺- n -苯乙基哌啶(4-ANPP)的存在或不存在。结果:806例标本中,786例(98%)免疫检测结果一致,20例(2%)免疫检测结果不一致。免疫测定法与LC-MS/MS之间LZI测定法的一致性为97%,DRI测定法的一致性为89%。183例标本中检出4-ANPP 13例(7%)。讨论:这两种检测方法在纳入尿药物筛查组方面具有可比性的临床效用。
{"title":"Comparison of the DRI II and LZI I fentanyl immunoassays for in vitro clinical diagnostic use.","authors":"Halimat Olaniyan, Jennifer Beckman, Elizabeth Crosby, David Shepherd, Rejwi A Dahal","doi":"10.1093/labmed/lmaf079","DOIUrl":"10.1093/labmed/lmaf079","url":null,"abstract":"<p><strong>Introduction: </strong>Fentanyl, a highly potent synthetic opioid, has contributed to a rapid rise in opioid-related overdoses and fatalities nationwide. Consequently, the need for accurate and timely testing for fentanyl has become critical. Immunoassay screens, reported as presumptive positive or negative, help address this need. We sought to compare the clinical performance of 2 US Food and Drug Administration (FDA)-approved fentanyl immunoassays-the Thermo Scientific DRI Fentanyl II Drugs of Abuse Assay and the Lin-Zhi International LZI Fentanyl (Q) Enzyme Immunoassay-for detection of fentanyl and its metabolites in urine, using liquid chromatography-tandem mass spectrometry (LC-MS/MS) as the reference method.</p><p><strong>Methods: </strong>A total of 806 urine specimens were screened using 2 FDA-approved fentanyl immunoassays on Beckman Coulter DxC 700 AU Chemistry Analyzer. Of these specimens, 183 that were both positive and negative by immunoassay were further analyzed by LC-MS/MS for the presence or absence of fentanyl, norfentanyl, and 4-anilino-N-phenethylpiperidine (4-ANPP).</p><p><strong>Results: </strong>Of the 806 specimens, 786 (98%) provided concordant results and 20 (2%) had discordant results between the 2 immunoassays. Concordance between immunoassays and LC-MS/MS was 97% for the LZI assay and 89% for the DRI assay. Among the 183 specimens tested, 4-ANPP was detected in 13 (7%).</p><p><strong>Discussion: </strong>The 2 assays demonstrated comparable clinical utility for incorporation into a urine drug screen panel.</p>","PeriodicalId":94124,"journal":{"name":"Laboratory medicine","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145608091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dinesh Jothimani, Sathish Srinivasan, Evangeline Simon, Lexmi Priya Raju, Hemalatha Ramachandran, Abraham Sam Rajan, Komalavalli Subbiah, Mukul Vij, Mohamed Rela
Introduction: Hepatocellular carcinoma (HCC) diagnosis requires a combination of elevated ɑ-fetoprotein (AFP) levels and liver imaging. We evaluated the role of prothrombin induced by vitamin K antagonist-II (PIVKA-II) in patients with suspected HCC.
Methods: A retrospective analysis was conducted on adult Indian patients with suspected HCC who had elevated AFP and PIVKA-II levels and had undergone radiologic investigation.
Results: Among 178 suspected cases, 144 (80.99%) were diagnosed with HCC; the median age of these 144 patients was 62 years (IQR, 54-68 years). The median AFP and PIVKA-II levels were 14.68 ng/mL (IQR, 3.83-146.50 ng/mL) and 354.50 ng/mL (IQR, 49.41-4293.40 ng/mL), respectively. The sensitivity and specificity were 52.08% and 88.24% for AFP (≥10 ng/mL) and 80.56% and 32.35% for PIVKA-II (≥40 ng/mL). The false positivity rate of PIVKA-II was 67.60%. PIVKA-II showed moderate correlation (r = 0.413) with HCC size and was more reliable than AFP for HCC lesions larger than 5 cm (area under the curve = 0.731 vs 0.627). PIVKA-II levels were lower following therapy for HCC (682.98-122.50 ng/mL; P < .001) than AFP levels (15.05-6.50 ng/mL; P = .30). Among AFP-negative patients with HCC, 68.10% had elevated PIVKA-II levels.
Discussion: With its higher false positivity rate, PIVKA-II may not be a reliable marker for HCC, although it may be useful in larger HCC lesions and in AFP-negative patients. Establishing a newer cutoff value for PIVKA-II among the Indian population may improve its specificity in the diagnosis and management of HCC.
{"title":"Hepatocellular carcinoma: PIVKA-II may be unsuitable for Indian patients.","authors":"Dinesh Jothimani, Sathish Srinivasan, Evangeline Simon, Lexmi Priya Raju, Hemalatha Ramachandran, Abraham Sam Rajan, Komalavalli Subbiah, Mukul Vij, Mohamed Rela","doi":"10.1093/labmed/lmaf065","DOIUrl":"10.1093/labmed/lmaf065","url":null,"abstract":"<p><strong>Introduction: </strong>Hepatocellular carcinoma (HCC) diagnosis requires a combination of elevated ɑ-fetoprotein (AFP) levels and liver imaging. We evaluated the role of prothrombin induced by vitamin K antagonist-II (PIVKA-II) in patients with suspected HCC.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on adult Indian patients with suspected HCC who had elevated AFP and PIVKA-II levels and had undergone radiologic investigation.</p><p><strong>Results: </strong>Among 178 suspected cases, 144 (80.99%) were diagnosed with HCC; the median age of these 144 patients was 62 years (IQR, 54-68 years). The median AFP and PIVKA-II levels were 14.68 ng/mL (IQR, 3.83-146.50 ng/mL) and 354.50 ng/mL (IQR, 49.41-4293.40 ng/mL), respectively. The sensitivity and specificity were 52.08% and 88.24% for AFP (≥10 ng/mL) and 80.56% and 32.35% for PIVKA-II (≥40 ng/mL). The false positivity rate of PIVKA-II was 67.60%. PIVKA-II showed moderate correlation (r = 0.413) with HCC size and was more reliable than AFP for HCC lesions larger than 5 cm (area under the curve = 0.731 vs 0.627). PIVKA-II levels were lower following therapy for HCC (682.98-122.50 ng/mL; P < .001) than AFP levels (15.05-6.50 ng/mL; P = .30). Among AFP-negative patients with HCC, 68.10% had elevated PIVKA-II levels.</p><p><strong>Discussion: </strong>With its higher false positivity rate, PIVKA-II may not be a reliable marker for HCC, although it may be useful in larger HCC lesions and in AFP-negative patients. Establishing a newer cutoff value for PIVKA-II among the Indian population may improve its specificity in the diagnosis and management of HCC.</p>","PeriodicalId":94124,"journal":{"name":"Laboratory medicine","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145575198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Correction to: Evaluation of CD73, PD-1, circHIPK3, and circNRIP1 expression in the peripheral blood of patients with colorectal cancer.","authors":"","doi":"10.1093/labmed/lmaf063","DOIUrl":"10.1093/labmed/lmaf063","url":null,"abstract":"","PeriodicalId":94124,"journal":{"name":"Laboratory medicine","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145764706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yangyang Wu, Kaili Qin, Liqun Xiang, Meiling Luo, Min Chen, Xinyan Chen, Jie Yan, Weijie Zhou, Faquan Lin, Lin Liao
Introduction: Congenital hypofibrinogenemia is a genetic disorder caused by defects in the fibrinogen gene. We identified a case of congenital hypofibrinogenemia with mutations in the FGA, FGB, and FGG genes associated with bleeding risk and conducted experimental studies to explore the condition's pathogenesis.
Methods: To investigate the bleeding risk in the proband, we performed coagulation screening and genetic analysis, supplemented by sodium dodecyl sulfate polyacrylamide gel electrophoresis, electron microscopy, sequence conservation analysis, and thromboelastography to elucidate the pathogenic mechanism.
Results: Fibrinogen levels in the proband's plasma were measured by 3 methods: 0.81 g/L (Clauss assay), 0.95 g/L (prothrombin time derived), and 0.87 g/L (enzyme-linked immunosorbent assay). The proband and her father had c.37T > C (p.Tyr13His) in the FGG gene; c.959-16_959-13delTTTG deletion mutation, c.567C > T (p.Ser189=), c.1125C > T (p.Tyr375=), c.1433G > A (p.Arg478Lys), and c.1433G > A (p.Arg478Lys) in the FGB gene; and c.991A > G (p.Thr331Ala) in the FGA gene. Scanning electron microscope analysis showed that the proband's fibrin fibers were fine, with a loose spatial structure and increased pore size.
Discussion: The c.959-16_959-13delTTTG deletion is the main cause of congenital hypofibrinogenemia in this family. The γTyr13His heterozygous mutation may have a minor impact on the structure and function of the fibrinogen molecule. The Bβ(Ser189=, Tyr375=, Arg478Lys) and AαThr331Ala mutations may have a certain impact on the proband's clinical phenotype.
简介:先天性低纤维蛋白原血症是一种由纤维蛋白原基因缺陷引起的遗传性疾病。我们发现了一例先天性低纤维蛋白原血症,FGA、FGB和FGG基因突变与出血风险相关,并进行了实验研究以探索其发病机制。方法:对先证患者进行凝血筛查和遗传分析,辅以十二烷基硫酸钠聚丙烯酰胺凝胶电泳、电镜、序列保守分析和血栓弹性成像,探讨其发病机制。结果:先证者血浆纤维蛋白原水平采用3种方法测定:0.81 g/L (Clauss法)、0.95 g/L(凝血酶原时间衍生法)、0.87 g/L(酶联免疫吸附法)。先证者及其父亲在FGG基因中有C . 37t > C (p.Tyr13His);FGB基因c.959-16_959-13delTTTG缺失突变,c.567C > T (p.Ser189=), c.1125C > T (p.Tyr375=), c.1433G > A (p.Arg478Lys), c.1433G > A (p.Arg478Lys);FGA基因中的c.991A > G (p.Thr331Ala)。扫描电镜分析显示,先证者的纤维蛋白纤维较细,空间结构疏松,孔径增大。讨论:c.959-16_959-13delTTTG缺失是该家族先天性低纤维蛋白原血症的主要原因。γTyr13His杂合突变可能对纤维蛋白原分子的结构和功能有轻微的影响。Bβ(Ser189=, Tyr375=, Arg478Lys)和a α thr331ala突变可能对先证者的临床表型有一定影响。
{"title":"Congenital hypofibrinogenemia with bleeding risk: mutations in the FGA, FGB, and FGG genes.","authors":"Yangyang Wu, Kaili Qin, Liqun Xiang, Meiling Luo, Min Chen, Xinyan Chen, Jie Yan, Weijie Zhou, Faquan Lin, Lin Liao","doi":"10.1093/labmed/lmaf042","DOIUrl":"10.1093/labmed/lmaf042","url":null,"abstract":"<p><strong>Introduction: </strong>Congenital hypofibrinogenemia is a genetic disorder caused by defects in the fibrinogen gene. We identified a case of congenital hypofibrinogenemia with mutations in the FGA, FGB, and FGG genes associated with bleeding risk and conducted experimental studies to explore the condition's pathogenesis.</p><p><strong>Methods: </strong>To investigate the bleeding risk in the proband, we performed coagulation screening and genetic analysis, supplemented by sodium dodecyl sulfate polyacrylamide gel electrophoresis, electron microscopy, sequence conservation analysis, and thromboelastography to elucidate the pathogenic mechanism.</p><p><strong>Results: </strong>Fibrinogen levels in the proband's plasma were measured by 3 methods: 0.81 g/L (Clauss assay), 0.95 g/L (prothrombin time derived), and 0.87 g/L (enzyme-linked immunosorbent assay). The proband and her father had c.37T > C (p.Tyr13His) in the FGG gene; c.959-16_959-13delTTTG deletion mutation, c.567C > T (p.Ser189=), c.1125C > T (p.Tyr375=), c.1433G > A (p.Arg478Lys), and c.1433G > A (p.Arg478Lys) in the FGB gene; and c.991A > G (p.Thr331Ala) in the FGA gene. Scanning electron microscope analysis showed that the proband's fibrin fibers were fine, with a loose spatial structure and increased pore size.</p><p><strong>Discussion: </strong>The c.959-16_959-13delTTTG deletion is the main cause of congenital hypofibrinogenemia in this family. The γTyr13His heterozygous mutation may have a minor impact on the structure and function of the fibrinogen molecule. The Bβ(Ser189=, Tyr375=, Arg478Lys) and AαThr331Ala mutations may have a certain impact on the proband's clinical phenotype.</p>","PeriodicalId":94124,"journal":{"name":"Laboratory medicine","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145515375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Rapid and accurate identification of pathogens is essential for managing lung infections in patients following kidney transplantation. This study aimed to compare the diagnostic performance and clinical utility of conventional detection methods and metagenomic next-generation sequencing (NGS) in kidney transplant recipients with respiratory infections.
Methods: We conducted a retrospective analysis of metagenomic NGS and conventional detection method results in 71 patients, examining the spectrum of pathogen detection characteristics between the 2 methods.
Results: The overall positivity rate of conventional detection methods was statistically significantly lower than that of metagenomic NGS (61.97% vs 84.51%, P = .004). Among the 38 participants who tested positive by both methods, metagenomic NGS identified a greater number of pathogens than conventional detection methods. Following metagenomic NGS results, antibiotic therapy was modified in 71.83% of participants, leading to improved prognoses in 33.33% of patients. In additionally, metagenomic NGS demonstrated a shorter turnaround time than conventional detection methods. The most prevalent bacteria identified in pulmonary infections among kidney transplant recipients were Klebsiella pneumoniae, while cytomegalovirus was the most common virus and Pneumocystis jirovecii was the predominant fungus.
Discussion: This study offers preliminary insights into the spectrum of pathogens responsible for pulmonary infections following kidney transplantation, laying the foundation for better understanding their clinical characteristics. In patients with post-transplant pulmonary infections, metagenomic NGS outperforms conventional detection methods in terms of pathogen detection, speed, positivity rate, sensitivity, and ability to diagnose mixed infections.
快速准确地鉴定病原体对于处理肾移植后患者肺部感染至关重要。本研究旨在比较传统检测方法和新一代宏基因组测序(NGS)对肾移植受者呼吸道感染的诊断性能和临床应用。方法:回顾性分析71例患者宏基因组NGS和常规检测结果,比较两种方法的病原菌检测谱特征。结果:常规检测方法的总阳性率低于宏基因组NGS (61.97% vs 84.51%, P = 0.004)。在两种检测方法均呈阳性的38名参与者中,宏基因组NGS比传统检测方法鉴定出更多的病原体。宏基因组NGS结果显示,71.83%的参与者改变了抗生素治疗,33.33%的患者预后改善。此外,宏基因组NGS比传统检测方法的周转时间更短。肾移植受者肺部感染中最常见的细菌是肺炎克雷伯菌,而巨细胞病毒是最常见的病毒,而肺囊虫是主要的真菌。讨论:本研究提供了对肾移植后肺部感染病原体谱的初步认识,为更好地理解其临床特征奠定了基础。在移植后肺部感染患者中,宏基因组NGS在病原体检测、速度、阳性率、敏感性和诊断混合感染能力等方面优于传统检测方法。
{"title":"The clinical value of metagenomic next-generation sequencing for diagnosing pulmonary infections in kidney transplant recipients.","authors":"Xiaohong Qin, Panyan Liu, DaQing Lu, Tingting Lu, Chunhong Li, Zhenfeng Deng, Zhiang Liu","doi":"10.1093/labmed/lmaf035","DOIUrl":"10.1093/labmed/lmaf035","url":null,"abstract":"<p><strong>Introduction: </strong>Rapid and accurate identification of pathogens is essential for managing lung infections in patients following kidney transplantation. This study aimed to compare the diagnostic performance and clinical utility of conventional detection methods and metagenomic next-generation sequencing (NGS) in kidney transplant recipients with respiratory infections.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of metagenomic NGS and conventional detection method results in 71 patients, examining the spectrum of pathogen detection characteristics between the 2 methods.</p><p><strong>Results: </strong>The overall positivity rate of conventional detection methods was statistically significantly lower than that of metagenomic NGS (61.97% vs 84.51%, P = .004). Among the 38 participants who tested positive by both methods, metagenomic NGS identified a greater number of pathogens than conventional detection methods. Following metagenomic NGS results, antibiotic therapy was modified in 71.83% of participants, leading to improved prognoses in 33.33% of patients. In additionally, metagenomic NGS demonstrated a shorter turnaround time than conventional detection methods. The most prevalent bacteria identified in pulmonary infections among kidney transplant recipients were Klebsiella pneumoniae, while cytomegalovirus was the most common virus and Pneumocystis jirovecii was the predominant fungus.</p><p><strong>Discussion: </strong>This study offers preliminary insights into the spectrum of pathogens responsible for pulmonary infections following kidney transplantation, laying the foundation for better understanding their clinical characteristics. In patients with post-transplant pulmonary infections, metagenomic NGS outperforms conventional detection methods in terms of pathogen detection, speed, positivity rate, sensitivity, and ability to diagnose mixed infections.</p>","PeriodicalId":94124,"journal":{"name":"Laboratory medicine","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145380359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dana Duzan, Karen Fong, Vicki S Freeman, Nancy Goodyear, Teresa S Nadder, Alexa Siddon, Amy Spiczka, Teresa Taff, Patricia Tanabe
The American Society for Clinical Pathology Board of Certification Research and Development Committee has undertaken regular surveys of Medical Laboratory Science (MLS) education programs. Results of previous surveys were reported in 2019 and 2022. The purpose of these recurring surveys is to support MLS programs in their educational mission by providing information about current issues and trends that may affect program resources and MLS education, including data for grant applications, funding requests, and strategic planning. Program-related topics covered in the surveys included program director and faculty education and certification requirements, program structure and duration, student grade point averages and acceptance data, clinical site numbers and status, and faculty numbers and vacancies.
{"title":"ASCP Board of Certification survey of Medical Laboratory Science education 2023: programs.","authors":"Dana Duzan, Karen Fong, Vicki S Freeman, Nancy Goodyear, Teresa S Nadder, Alexa Siddon, Amy Spiczka, Teresa Taff, Patricia Tanabe","doi":"10.1093/labmed/lmaf069","DOIUrl":"10.1093/labmed/lmaf069","url":null,"abstract":"<p><p>The American Society for Clinical Pathology Board of Certification Research and Development Committee has undertaken regular surveys of Medical Laboratory Science (MLS) education programs. Results of previous surveys were reported in 2019 and 2022. The purpose of these recurring surveys is to support MLS programs in their educational mission by providing information about current issues and trends that may affect program resources and MLS education, including data for grant applications, funding requests, and strategic planning. Program-related topics covered in the surveys included program director and faculty education and certification requirements, program structure and duration, student grade point averages and acceptance data, clinical site numbers and status, and faculty numbers and vacancies.</p>","PeriodicalId":94124,"journal":{"name":"Laboratory medicine","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145575205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Patients with rheumatoid arthritis (RA) can develop interstitial lung disease (ILD) with increased morbidity and mortality. The diagnostic values of serum carcinoembryonic antigen (CEA), cancer antigen (CA) 125, and human epididymis protein 4 (HE4) in these patients was unclear.
Methods: A cross-sectional study enrolled patients with RA and healthy control individuals from January 2020 to August 2024. Demographics, disease duration, high-resolution computed tomography scan images, and laboratory test results were collected and analyzed.
Results: The cohort comprised 87 patients with RA (40 with and 47 without ILD) and 82 healthy individuals. Serum CEA, CA125, and HE4 levels were clinically significantly higher in patients with RA than in healthy control individuals; they were also elevated in patients with RA and ILD compared with patients with RA but not ILD. Increased levels of CEA, CA125, and HE4 were associated with more severe impairments in pulmonary function. Each biomarker demonstrated satisfactory performance, with the combination of all 3 yielding the highest efficacy (sensitivity = 95.00%, specificity = 95.74%, area under the curve = 0.993) for evaluating ILD.
Discussion: Serum CEA, CA125, and HE4 levels were clinically significantly elevated in patients with RA, particularly in those patients with ILD, and higher levels correlated with poorer pulmonary function. Their combination could facilitate accurate assessment of RA-associated ILD.
{"title":"Clinical significance and pulmonary function assessment by serum CEA, CA125, and HE4 measurements in patients with rheumatoid arthritis and interstitial lung disease: a cross-sectional study.","authors":"Hao Zhang, Ningning Li, Hanwen Deng, Bingbing Dai","doi":"10.1093/labmed/lmaf077","DOIUrl":"10.1093/labmed/lmaf077","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with rheumatoid arthritis (RA) can develop interstitial lung disease (ILD) with increased morbidity and mortality. The diagnostic values of serum carcinoembryonic antigen (CEA), cancer antigen (CA) 125, and human epididymis protein 4 (HE4) in these patients was unclear.</p><p><strong>Methods: </strong>A cross-sectional study enrolled patients with RA and healthy control individuals from January 2020 to August 2024. Demographics, disease duration, high-resolution computed tomography scan images, and laboratory test results were collected and analyzed.</p><p><strong>Results: </strong>The cohort comprised 87 patients with RA (40 with and 47 without ILD) and 82 healthy individuals. Serum CEA, CA125, and HE4 levels were clinically significantly higher in patients with RA than in healthy control individuals; they were also elevated in patients with RA and ILD compared with patients with RA but not ILD. Increased levels of CEA, CA125, and HE4 were associated with more severe impairments in pulmonary function. Each biomarker demonstrated satisfactory performance, with the combination of all 3 yielding the highest efficacy (sensitivity = 95.00%, specificity = 95.74%, area under the curve = 0.993) for evaluating ILD.</p><p><strong>Discussion: </strong>Serum CEA, CA125, and HE4 levels were clinically significantly elevated in patients with RA, particularly in those patients with ILD, and higher levels correlated with poorer pulmonary function. Their combination could facilitate accurate assessment of RA-associated ILD.</p>","PeriodicalId":94124,"journal":{"name":"Laboratory medicine","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145679928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}